FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062592279> ?p ?o ?g. }

• W2062592279 endingPage "425" @default.
• W2062592279 startingPage "422" @default.
• W2062592279 abstract "Pediatric TransplantationVolume 7, Issue 6 p. 422-425 Novel treatment for refractory acute myeloid leukemia Olle Ringdén, Olle Ringdén Professor of Transplantation Immunology Centre for Allogeneic Stem Cell Transplantation Division of Clinical Immunology F79, Huddinge University Hospital SE-141 86 Stockholm Sweden Tel.: +46 8 585 82672 Fax: +46 8 746 6699 E-mail: [email protected]Search for more papers by this author Olle Ringdén, Olle Ringdén Professor of Transplantation Immunology Centre for Allogeneic Stem Cell Transplantation Division of Clinical Immunology F79, Huddinge University Hospital SE-141 86 Stockholm Sweden Tel.: +46 8 585 82672 Fax: +46 8 746 6699 E-mail: [email protected]Search for more papers by this author First published: 12 November 2003 https://doi.org/10.1046/j.1397-3142.2003.00106.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977: 49: 511–533. 2 Storb R, Thomas ED. Allogeneic bone-marrow transplantation. Immunol Rev 1983: 71: 77–102. 3 Ringdén O. Allogeneic bone marrow transplantation for hematological malignancies – controversies and recent advances. Acta Oncol 1997: 36: 549–564. 4 Santos WG. Workshop summary: preparative regimens for allogeneic bone marrow transplantation in leukemia. In: RP Gale, R Champlin , ed. Progress in Bone Marrow Transplantation. New York: Alan R. Liss, inc., 1987: pp. 113–119. 5 Ringdén O, Zwaan FE, Hermans J, Gratwohl A, for the Leukemia Working party of the European Group for Bone Marrow Transplantation. European experience of bone marrow transplantation for leukemia. Transplant Proc 1987: 19: 2600–2604. 6 Santos W. Problems and strategies for bone marrow transplantation in acute leukemia and chronic myelogenous leukemia. Cancer Detect Prev 1988: 12: 589. 7 Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study. Blood 1993: 81: 2187–2193. 8 Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001: 98: 3569–3574. 9 Ringdén O, Ruutu T, Remberger M, et al., for the Nordic Bone Marrow Transplantation Group. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 1994: 83: 2723–2730. 10 Blume KG, Forman SJ, O'Donnel, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987: 69: 1015–1020. 11 Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990: 76: 1867–1871. 12 Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997: 89: 4531–4536. 13 Slavin S, Nagler A, Naparstek E, et al. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756–763. 14 McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999: 5: 92–203. 15 Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529–1533. 16 Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555–562. 17 Ringdén O, Labopin M, Gluckman E, et al. and Gorin NC for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplantation 1996: 18: 921–929. 18 Ringdén O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A for the Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leuk Lymphoma 1996: 24: 71–79. 19 Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Int Med 1988: 108: 806–814. 20 Marmont AM , Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120–2130. 21 Aschan J, Ringdén O, Sundberg B, Klaesson S, Ljungman P, Lönnqvist B. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 1993: 50: 269–274. 22 Fefer A, Sullivan KM, Weiden P, et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than syngeneic marrow transplantation. In: RL Truitt, RP Gale, MM Bortin, eds. Cellular Immunotherapy of Cancer. New York: A R Liss, 1987: pp. 401–408. 23 Barrett J, Ringdén O, Zhang M-J et al., and the GVHD/GVL Working Committee of the International Bone Marrow Transplant Registry. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia. Blood 2000: 95: 3323–3327. 24 Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977: 296: 61–66. 25 Bortin MM, Gale RP, Kay HEM, Rimm AA. Bone marrow transplantation for acute myelogenous leukemia: Factors associated with early mortality. JAMA 1983: 249: 1166–1175. 26 Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985: 40: 39–44. 27 Paulin T. Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant 1992: 6: 48–54. 28 Tollemar J, Ringdén O, Boström L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989: 4: 635–641. 29 Ringdén O, Barrett J, Zhang M-J, et al., and the GVHD/GVL Working Committees. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003: 121: 874–885. 30 Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997: 90: 4705–4709. 31 Ringdén O, Labopin M, Bacigalupo A, et al. for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002: 20: 4655–4664. 32 Gur H , Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 2002: 99: 4174–4181. 33 Martelli MF, Reisner Y. Haploidentical ‘megadose’ CD34+ cell transplant for patients with acute leukemia. Leukemia 2002: 16: 404–405. 34 Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001: 15: 111–119. 35 Kolb HJ, Mittermüller J, Clemm CH, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990: 76: 2462–2465. 36 Kolb HJ, Schattenberg A, Goldman J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995: 86: 2041–2050. 37 Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995: 86: 1261. 38 Carlens S , Remberger M, Aschan J, Ringdén O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biology of Blood and Marrow Transplantation 2001: 7: 31–38. 39 Dazzi F , Szydlo M, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000: 95: 67–71. 40 Bolger GB, Sullivan KM, Storb R, et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986: 1: 21–30. 41 Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994: 14: 73–77. 42 Remberger M, Ringdén O, Ljungman P, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998: 22: 73–78. Volume7, Issue6December 2003Pages 422-425 ReferencesRelatedInformation" @default.
• W2062592279 created "2016-06-24" @default.
• W2062592279 creator A5003097876 @default.
• W2062592279 date "2003-11-12" @default.
• W2062592279 modified "2023-09-23" @default.
• W2062592279 title "Novel treatment for refractory acute myeloid leukemia" @default.
• W2062592279 cites W1274344746 @default.
• W2062592279 cites W1479909146 @default.
• W2062592279 cites W1522048276 @default.
• W2062592279 cites W1536678688 @default.
• W2062592279 cites W1545991364 @default.
• W2062592279 cites W1589162162 @default.
• W2062592279 cites W1707184873 @default.
• W2062592279 cites W1966838831 @default.
• W2062592279 cites W1969756786 @default.
• W2062592279 cites W1996389468 @default.
• W2062592279 cites W2002024986 @default.
• W2062592279 cites W2022625735 @default.
• W2062592279 cites W2045477167 @default.
• W2062592279 cites W2051262064 @default.
• W2062592279 cites W2067480394 @default.
• W2062592279 cites W2076272123 @default.
• W2062592279 cites W2083434602 @default.
• W2062592279 cites W2084886561 @default.
• W2062592279 cites W2104353116 @default.
• W2062592279 cites W2113764318 @default.
• W2062592279 cites W2121945260 @default.
• W2062592279 cites W2149131140 @default.
• W2062592279 cites W2167541030 @default.
• W2062592279 cites W2292001986 @default.
• W2062592279 cites W2314734471 @default.
• W2062592279 cites W3021273376 @default.
• W2062592279 cites W3112116562 @default.
• W2062592279 cites W4229907744 @default.
• W2062592279 cites W4244166141 @default.
• W2062592279 cites W4246085869 @default.
• W2062592279 cites W44995847 @default.
• W2062592279 cites W66769540 @default.
• W2062592279 doi "https://doi.org/10.1046/j.1397-3142.2003.00106.x" @default.
• W2062592279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14870888" @default.
• W2062592279 hasPublicationYear "2003" @default.
• W2062592279 type Work @default.
• W2062592279 sameAs 2062592279 @default.
• W2062592279 citedByCount "0" @default.
• W2062592279 crossrefType "journal-article" @default.
• W2062592279 hasAuthorship W2062592279A5003097876 @default.
• W2062592279 hasConcept C121332964 @default.
• W2062592279 hasConcept C126322002 @default.
• W2062592279 hasConcept C142424586 @default.
• W2062592279 hasConcept C177713679 @default.
• W2062592279 hasConcept C2778461978 @default.
• W2062592279 hasConcept C2778729363 @default.
• W2062592279 hasConcept C2779282312 @default.
• W2062592279 hasConcept C71924100 @default.
• W2062592279 hasConcept C87355193 @default.
• W2062592279 hasConceptScore W2062592279C121332964 @default.
• W2062592279 hasConceptScore W2062592279C126322002 @default.
• W2062592279 hasConceptScore W2062592279C142424586 @default.
• W2062592279 hasConceptScore W2062592279C177713679 @default.
• W2062592279 hasConceptScore W2062592279C2778461978 @default.
• W2062592279 hasConceptScore W2062592279C2778729363 @default.
• W2062592279 hasConceptScore W2062592279C2779282312 @default.
• W2062592279 hasConceptScore W2062592279C71924100 @default.
• W2062592279 hasConceptScore W2062592279C87355193 @default.
• W2062592279 hasIssue "6" @default.
• W2062592279 hasLocation W20625922791 @default.
• W2062592279 hasLocation W20625922792 @default.
• W2062592279 hasOpenAccess W2062592279 @default.
• W2062592279 hasPrimaryLocation W20625922791 @default.
• W2062592279 hasRelatedWork W1493011226 @default.
• W2062592279 hasRelatedWork W1967493696 @default.
• W2062592279 hasRelatedWork W200513925 @default.
• W2062592279 hasRelatedWork W2121159001 @default.
• W2062592279 hasRelatedWork W2150998544 @default.
• W2062592279 hasRelatedWork W2414586291 @default.
• W2062592279 hasRelatedWork W2419389668 @default.
• W2062592279 hasRelatedWork W2560841524 @default.
• W2062592279 hasRelatedWork W2791968852 @default.
• W2062592279 hasRelatedWork W4308735896 @default.
• W2062592279 hasVolume "7" @default.
• W2062592279 isParatext "false" @default.
• W2062592279 isRetracted "false" @default.
• W2062592279 magId "2062592279" @default.
• W2062592279 workType "article" @default.